

David T Rubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/309598/publications.pdf>

Version: 2024-02-01

232
papers

10,589
citations

44069

48
h-index

40979

93
g-index

234
all docs

234
docs citations

234
times ranked

9005
citing authors

#	ARTICLE	IF	CITATIONS
1	Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2407-2409.e2.	4.4	7
2	Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center. <i>Digestive Diseases and Sciences</i> , 2023, 68, 385-388.	2.3	14
3	Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 293-302.e9.	4.4	27
4	Using Wearable Biosensors to Predict Length of Stay for Patients with IBD After Bowel Surgery. <i>Digestive Diseases and Sciences</i> , 2022, 67, 844-853.	2.3	8
5	Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 553-559.	1.9	9
6	Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease. <i>Intestinal Research</i> , 2022, 20, 303-312.	2.6	7
7	Stratifying Risks of Ileal Pouch Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1620-1621.	4.4	2
8	Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 17-21.	1.3	14
9	Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 302-310.	3.7	16
10	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	2.0	24
11	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 69-95.	8.1	41
12	What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?. <i>Gastroenterology</i> , 2022, 162, 1396-1408.	1.3	49
13	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	8.1	18
14	Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-to-Anal Anastomosis in Pediatric Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1386-1394.	1.9	9
15	A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1549-1554.	1.9	10
16	Entering the Era of Disease Modification in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 1367-1369.	1.3	6
17	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. <i>Intestinal Research</i> , 2022, 20, 240-250.	2.6	10
18	Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget. <i>World Journal of Gastrointestinal Endoscopy</i> , 2022, 14, 85-95.	1.2	3

#	ARTICLE	IF	CITATIONS
19	IL-23 Monoclonal Antibodies for IBD: So Many, So Different?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, ii42-ii53.	1.3	10
20	Hypertensive Emergency After Initiating Ozanimod: A Case Report. <i>Inflammatory Bowel Diseases</i> , 2022, 28, e114-e115.	1.9	1
21	The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2427-2434.	4.4	14
22	Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel Disease. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1279-1280.	1.9	2
23	Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4020-4031.	2.3	5
24	Self-Reported Failure to Address Sexual Function in Patients With Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1465-1468.	1.9	3
25	A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. <i>Crohn's & Colitis</i> 360, 2022, 4, .	1.1	2
26	Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, , .	1.9	1
27	Intestinal Cancer and Dysplasia in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 369-379.	2.2	2
28	Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 6-27.	3.7	17
29	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2207-2209.e3.	4.4	20
30	Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1096-1106.	1.9	15
31	The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1201-1209.	1.9	6
32	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1008-1016.	1.9	12
33	Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2333-2342.	4.4	19
34	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1130-1141.	1.3	37
35	An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2524-2531.	4.4	5
36	Black Race and Public Insurance Are Predictive of Inappropriate Evaluation of Iron Deficiency Anemia and Diarrhea. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2200-2206.	2.3	11

#	ARTICLE	IF	CITATIONS
37	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1592-1601.e3.	4.4	69
38	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 236-241.	1.9	18
39	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 104-110.	4.4	60
40	Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 203-206.	1.9	27
41	Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 836-847.	1.9	21
42	Emerging treatment options for extraintestinal manifestations in IBD. <i>Gut</i> , 2021, 70, 796-802.	12.1	45
43	Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	14
44	Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment. <i>Intestinal Research</i> , 2021, 19, 1-11.	2.6	23
45	Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	2
46	SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. <i>Gut</i> , 2021, 70, 635-640.	12.1	173
47	Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. <i>Gastroenterology</i> , 2021, 160, 639-644.	1.3	12
48	Vedolizumab and Anti-Tumour Necrosis Factor \pm Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1694-1706.	1.3	62
49	Dissemination of Gastroenterology and Hepatology Research on Social Media Platforms Is Associated With Increased Citation Count. <i>American Journal of Gastroenterology</i> , 2021, 116, 2137-2139.	0.4	9
50	Clinical and Translational Considerations for Understanding Depression and Anxiety in Patients with Inflammatory Bowel Disease. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-7.	1.5	7
51	How to Integrate a Medical Ethics Curriculum into Gastroenterology Fellowships. <i>Gastroenterology</i> , 2021, 160, 1003-1006.	1.3	0
52	COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. <i>Gastroenterology</i> , 2021, 160, 1447-1451.	1.3	11
53	Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 313-319.	2.3	7
54	455 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON ENDOSCOPIC OUTCOME MEASURES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY. <i>Gastroenterology</i> , 2021, 160, S-91.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. <i>World Journal of Gastroenterology</i> , 2021, 27, 2521-2530.	3.3	8
56	Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2785-2793.	2.8	3
57	Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis. <i>ACG Case Reports Journal</i> , 2021, 8, e00604.	0.4	17
58	Reply. <i>Gastroenterology</i> , 2021, 160, 2627.	1.3	1
59	Response to Tetangco and Hanauer. <i>American Journal of Gastroenterology</i> , 2021, 116, 1959-1960.	0.4	0
60	Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 985-997.	3.0	35
61	Management of code status in the periendoscopic period: a national survey of current practices and beliefs of U.S. gastroenterologists. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 172-177.e2.	1.0	0
62	Identification of Risk Factors for Coexisting Sinusitis and Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	1
63	Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	2
64	Reply. <i>Gastroenterology</i> , 2021, 161, 369-370.	1.3	0
65	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. <i>Gastroenterology</i> , 2021, 161, 715-718.e4.	1.3	102
66	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	17.8	56
67	ULCERATIVE COLITIS PATIENTS HAVE REDUCED RECTAL COMPLIANCE COMPARED WITH NON-IBD CONTROLS. <i>Gastroenterology</i> , 2021, , .	1.3	8
68	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 826-849.	8.1	69
69	Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. <i>Gastroenterology</i> , 2021, 161, 1118-1132.	1.3	267
70	International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1942-1953.	1.9	30
71	Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 125-133.	0.4	10
72	A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 59-66.	0.1	0

#	ARTICLE	IF	CITATIONS
73	CANCER PREVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Practical Gastroenterology</i> , 2021, 45, 12-28.	4.0	0
74	Inflammatory Bowel Disease Patientsâ€™ Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	3
75	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohnâ€™s Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	1.9	17
76	Poor Sleep Quality in Crohnâ€™s Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1251-1259.	1.9	20
77	The Cost of Inflammatory Bowel Disease: An Initiative From the Crohnâ€™s & Colitis Foundation. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1-10.	1.9	274
78	Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 987-988.e1.	4.4	4
79	Inpatient Management of Inflammatory Bowel Disease-Related Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1346-1355.	4.4	21
80	Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2637-2642.	1.7	3
81	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroidâ€refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 637-643.	3.7	37
82	Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician. <i>American Journal of Gastroenterology</i> , 2020, 115, 1566-1569.	0.4	8
83	Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease. <i>ACG Case Reports Journal</i> , 2020, 7, e00449.	0.4	3
84	Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy. <i>Crohn's & Colitis</i> 360, 2020, 2, .	1.1	8
85	Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S774-S779.	1.3	26
86	Listening to the Patient: Improving the Design and Conduct of Clinical Trials in Inflammatory Bowel Diseases. <i>Crohn's & Colitis</i> 360, 2020, 2, .	1.1	2
87	Longâ€term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	3.7	97
88	Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 159, 2052-2064.	1.3	48
89	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2020, 27, 1620-1625.	1.9	7
90	Practical advice for management of inflammatory bowel diseases patients during the COVIDâ€19 pandemic: World Endoscopy Organization Statement. <i>Digestive Endoscopy</i> , 2020, 32, 658-662.	2.3	12

#	ARTICLE	IF	CITATIONS
91	Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 971-973.	1.9	31
92	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1365-1372.	3.7	8
93	Re: 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2247-2247.	6.4	3
94	Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1765-1768.	1.3	0
95	Periendoscopic code status. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 453.	1.0	1
96	Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 54-72.	3.7	93
97	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. <i>Gastroenterology</i> , 2020, 159, 6-13.e6.	1.3	185
98	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. <i>Gastroenterology</i> , 2020, 159, 350-357.	1.3	203
99	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1345-1353.	1.3	9
100	Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1676-1682.	3.7	14
101	Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 205-206.	4.4	21
102	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 486-493.	4.4	76
103	<p>Patient and physician preferences for ulcerative colitis treatments in the United States</p>. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 263-278.	2.3	27
104	PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. <i>Revista Médica Clínica Las Condes</i> , 2019, 30, 339-343.	0.2	0
105	<p>Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1545-1556.	1.8	13
106	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2090-2095.	2.8	6
107	The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 405-419.	1.4	0
108	Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. <i>Human Pathology</i> , 2019, 89, 44-50.	2.0	21

#	ARTICLE	IF	CITATIONS
109	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. <i>GastroHep</i> , 2019, 1, 108-117.	0.6	3
110	Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3596-3601.	2.3	50
111	Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 770-779.	0.9	28
112	Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1158-1162.	1.3	30
113	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 269-275.	1.0	36
114	Cyclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1105-1110.	1.3	24
115	Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1012-1024.	1.3	35
116	Real-World Experience with Tofacitinib in IBD at a Tertiary Center. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1945-1951.	2.3	80
117	IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 884-893.	1.3	15
118	Simplification of Validated Patient-Reported Outcome Instruments in Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2019, 1, .	1.1	0
119	Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1344-1351.	1.3	19
120	Histologic Remission in Ulcerative Colitis: Are We There Yet?. <i>American Journal of Gastroenterology</i> , 2019, 114, 713-715.	0.4	5
121	ACG Clinical Guideline: Ulcerative Colitis in Adults. <i>American Journal of Gastroenterology</i> , 2019, 114, 384-413.	0.4	933
122	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 50-57.	1.3	61
123	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 427-435.	1.9	36
124	836-Tofacitinib Efficacy in Patients With Moderate to Severe Ulcerative Colitis: Subgroup Analyses of OCTAVE Induction 1 & 2 and OCTAVE Sustain by 5-Aminosalicylates Use. <i>American Journal of Gastroenterology</i> , 2019, 114, S483-S484.	0.4	2
125	Role of Endoscopic Management in Ulcerative Colitis Patients with Dysplasia. , 2019, , 255-263.		0
126	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1294-1301.	2.3	53

#	ARTICLE	IF	CITATIONS
127	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 621-626.	1.3	77
128	Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36 Health Survey. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 600-609.	1.3	48
129	Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2135-2141.	1.9	30
130	Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1016-1024.	2.3	10
131	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1304-1309.	1.0	25
132	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 849-860.	1.9	34
133	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1291-1297.	1.9	3
134	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 145-156.	1.3	80
135	Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 68-74.	4.4	45
136	Emerging Therapies for Inflammatory Bowel Disease. <i>Advances in Therapy</i> , 2018, 35, 1746-1762.	2.9	77
137	Enteric infections complicating ulcerative colitis. <i>Intestinal Research</i> , 2018, 16, 489.	2.6	5
138	A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 933-940.	3.7	12
139	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw176.	1.3	141
140	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw177.	1.3	140
141	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1557-1564.e1.	4.4	157
142	Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. <i>Current Medical Research and Opinion</i> , 2017, 33, 837-843.	1.9	4
143	Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1180-1199.	1.3	323
144	miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. <i>Clinical Cancer Research</i> , 2017, 23, 5281-5291.	7.0	73

#	ARTICLE	IF	CITATIONS
145	Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 529-536.	1.9	7
146	Etrolizumab Treatment Improves Histological Activity as Assessed by the Roberts Histopathology Index. <i>Gastroenterology</i> , 2017, 152, S600.	1.3	1
147	Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 152-157.	1.9	110
148	The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 224-232.	1.9	28
149	Prevention of Colorectal Cancer in Inflammatory Bowel Disease Using Advanced Technologies. <i>Clinical Gastroenterology</i> , 2017, , 101-119.	0.0	0
150	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 229-239.e5.	4.4	164
151	Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 859-867.	0.9	46
152	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2017, 12, e0182900.	2.5	39
153	Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. <i>PLoS ONE</i> , 2017, 12, e0175099.	2.5	32
154	Clostridium Difficile Infection in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 902-911.	1.9	16
155	Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1027-1031.	1.9	20
156	Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 940-947.	1.9	29
157	Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1418-1424.	1.9	21
158	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 631-637.	1.9	27
159	Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 4-7.	0.7	2
160	Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 38-44.	0.7	10
161	Outcomes of colitis-associated dysplasia after referral from the community to a tertiary center. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 1078-1079.	1.0	12
162	Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 548-559.	3.2	15

#	ARTICLE	IF	CITATIONS
163	Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2972-2976.	2.3	27
164	Patient-Specific <i>Bacteroides</i> Genome Variants in Pouchitis. <i>MBio</i> , 2016, 7, .	4.1	38
165	Home Sweet Home? Will Medical Homes Be Coming to Your Neighborhood Sometime Soon?. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1981-1983.	1.9	1
166	Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G973-G988.	3.4	22
167	Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. <i>Current Gastroenterology Reports</i> , 2016, 18, 5.	2.5	29
168	Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 925-933.	1.3	24
169	Vedolizumab in the treatment of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 283-290.	3.0	12
170	Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 87-95.e1.	1.0	74
171	Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. <i>Intestinal Research</i> , 2016, 14, 202.	2.6	48
172	The Role of Biosimilars in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016, 12, 741-751.	0.1	6
173	Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3408-3417.	2.3	17
174	Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1709-1718.	1.9	52
175	Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 312-317.	1.3	35
176	SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, 639-651.e28.	1.3	625
177	SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 489-501.e26.	1.0	316
178	Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 1252-1256.	0.4	23
179	Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1852-1861.	1.7	13
180	Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2015, 11, 618-20.	0.1	2

#	ARTICLE	IF	CITATIONS
181	Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1569-1581.	1.3	388
182	Rescue Therapy with Cyclosporine or Infliximab is not Associated with an Increased Risk for Postoperative Complications in Patients Hospitalized for Severe Steroid-refractory Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 14-20.	1.9	47
183	A Rapid and Accurate Method to Detect Active Small Bowel Gastrointestinal Bleeding on Video Capsule Endoscopy. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2503-2507.	2.3	9
184	Describing the Clinical Phenotypes of Crohn's Disease: Lessons from the Past. <i>Digestive Diseases and Sciences</i> , 2014, 59, 6-8.	2.3	3
185	Introduction to the 80th Anniversary Issue of <i>Digestive Diseases and Sciences</i> . <i>Digestive Diseases and Sciences</i> , 2014, 59, 2-5.	2.3	2
186	Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1143-1155.	3.7	67
187	Clinical Presentation and Disease Course of Inflammatory Bowel Disease Differs by Race in a Large Tertiary Care Hospital. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2228-2235.	2.3	34
188	Chromoendoscopy for Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2014, 16, 407.	2.5	13
189	The Potential for Medical Therapy to Reduce the Risk of Colorectal Cancer and Optimize Surveillance in Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2014, 24, 353-365.	1.4	21
190	Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis. <i>ACG Case Reports Journal</i> , 2014, 1, 148-150.	0.4	6
191	Ethical considerations for clinical trials in inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2014, 10, 37-41.	0.1	5
192	43 Poor Sleep Quality Predicts Disease Relapse in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2013, 144, S-12.	1.3	7
193	Inflammation Is an Independent Risk Factor for Colonic Neoplasia in Patients With Ulcerative Colitis: A Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1601-1608.e4.	4.4	241
194	What You See is Not Always What You Get: Raising the Bar on Clinical Trial Methodology in Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 45-47.	1.3	3
195	Editorial: Curbing our Enthusiasm for Fecal Transplantation in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1631-1633.	0.4	28
196	Assessment of the Relationship Between Quality of Sleep and Disease Activity in Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2440-2443.	1.9	108
197	Colonoscopic Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in a Child. <i>American Journal of Gastroenterology</i> , 2012, 107, 1930-1931.	0.4	34
198	Joseph Barnett Kirsner, MD, PhD. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2722-2724.	2.3	1

#	ARTICLE	IF	CITATIONS
199	Fecal bacteriotherapy for ulcerative colitis: Patients are ready, are we?. Inflammatory Bowel Diseases, 2012, 18, 676-684.	1.9	69
200	Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial. Inflammatory Bowel Diseases, 2012, 18, 818-825.	1.9	26
201	Response to biologic therapy in Crohn's disease is improved with early treatment: An analysis of health claims data. Inflammatory Bowel Diseases, 2012, 18, 2225-2231.	1.9	68
202	Assessment of Variables Associated with Smoking Cessation in Crohn's Disease. Digestive Diseases and Sciences, 2012, 57, 1026-1032.	2.3	17
203	miR-143 and miR-145 are downregulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes. Inflammatory Bowel Diseases, 2012, 18, 94-100.	1.9	108
204	Infectious Proctitis: When to Suspect It Is Not Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2012, 57, 269-273.	2.3	76
205	New Findings in the Diagnosis and Prevention of Colorectal Cancer in IBD. , 2011, , 265-280.		0
206	A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Current Medical Research and Opinion, 2011, 27, 1803-1813.	1.9	9
207	Rifaximin Is Effective for the Treatment of Clostridium difficile-associated Diarrhea: Results of an Open-Label Pilot Study. Gastroenterology Research and Practice, 2011, 2011, 1-5.	1.5	30
208	Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut, 2011, 60, 937-943.	12.1	238
209	The Impact of Ulcerative Colitis on Patients' Lives Compared to Other Chronic Diseases: A Patient Survey. Digestive Diseases and Sciences, 2010, 55, 1044-1052.	2.3	57
210	The Peri-appendiceal Red Patch in Ulcerative Colitis: Review of the University of Chicago Experience. Digestive Diseases and Sciences, 2010, 55, 3495-3501.	2.3	36
211	Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. Medical Clinics of North America, 2010, 94, 155-178.	2.5	4
212	Impact of ulcerative colitis from patients' and physicians' perspectives. Inflammatory Bowel Diseases, 2009, 15, 581-588.	1.9	87
213	Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflammatory Bowel Diseases, 2009, 15, 750-755.	1.9	31
214	Do Colorectal Cancer Patients Understand That Their Family Is at Risk?. Digestive Diseases and Sciences, 2009, 54, 2473-2483.	2.3	16
215	Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2009, 38, 729-752.	2.2	6
216	Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterology and Hepatology, 2009, 5, 4-16.	0.1	11

#	ARTICLE	IF	CITATIONS
217	p53 Mutations are Associated with Dysplasia and Progression of Dysplasia in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2008, 53, 474-480.	2.3	24
218	An Updated Approach to Dysplasia in IBD. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 2153-2156.	1.7	8
219	Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 265-274.	1.9	70
220	Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. <i>Laboratory Investigation</i> , 2008, 88, 1110-1120.	3.7	297
221	Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 998-1004.	1.0	237
222	What is the most effective way to communicate results after endoscopy?. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 108-112.	1.0	60
223	Surveillance for Cancer and Dysplasia in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 581-604.	2.2	41
224	Surveillance of Dysplasia in Inflammatory Bowel Disease: The Gastroenterologist-Pathologist Partnership. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1309-1313.	4.4	37
225	Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1346-1350.	4.4	117
226	The Changing Face of Colorectal Cancer in Inflammatory Bowel Disease: Progress at Last!. <i>Gastroenterology</i> , 2006, 130, 1350-1352.	1.3	35
227	Colorectal cancer in inflammatory bowel disease: Molecular and clinical considerations. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 211-220.	0.8	21
228	To Test Or Not to Test: What are the Questions?. the Balanced Viewpoint. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 510-512.	1.9	6
229	Will a 5-ASA a Day Keep the Cancer (and Dysplasia) Away?. <i>American Journal of Gastroenterology</i> , 2005, 100, 1354-1356.	0.4	45
230	Virtual colonoscopy: A novel imaging modality for colorectal cancer. <i>Current Oncology Reports</i> , 2001, 3, 88-93.	4.0	6
231	Smoking and inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 855-862.	1.6	112
232	Ileal Desmoid Tumor in Ileal Crohn's: Coincidence or Connection?. <i>Digestive Diseases and Sciences</i> , 0, , .	2.3	0